Latest Hotspot

Preliminary Phase III Outcomes of Onfekafusp Alfa for Advanced Soft Tissue Sarcoma

23 February 2024
3 min read

Philogen S.p.A. is delighted to confirm the progression of the Phase III FIBROSARC clinical study, in accordance with the established protocol. This determination comes after the Independent Data and Safety Monitoring Board conducted a thorough assessment of the interim analysis data concerning the effectiveness and security of the trial.

👇Explore more about this drug by clicking the image below. Gain detailed insights into its R&D Status, Core Patent, Clinical Trials and Global Approval Status. Stay informed and updated.

图形用户界面, 文本, 应用程序, 电子邮件

描述已自动生成

The FIBROSARC clinical study is a stage III investigation that randomly allocates participants on a 1:1 basis to assess the impact of combining L19TNF with doxorubicin in comparison to the sole administration of doxorubicin to a group of 118 individuals undergoing initial treatment for advanced or metastatic Soft Tissue Sarcoma.

The primary endpoint for this clinical trial is the duration of Progression-Free Survival, anticipating a substantial 45% diminution in the likelihood of disease progression in the Experimental Arm. The interim analysis, which is an integral part of the study's design, was conducted after achieving half the number of events necessary for determining the primary endpoint.

The threshold of 46 events that constituted the trigger for the interim analysis was achieved on November 9, 2023. At the moment of issuing this press statement, the study has successfully recruited 97 of the 118 participants needed, spanning 24 different medical institutions across Germany, Italy, France, Poland, and Spain. The target is to finalize enrolment of all 118 participants by the year 2024.

Dr. Alfredo Covelli, serving as the Chief Medical Officer at Philogen, made the following statement: "Patients afflicted with advanced or metastatic STS continue to be subjected to chemotherapy protocols that garnered approval back in the 1970s. Despite the entry of cutting-edge treatments, such as immune checkpoint inhibitors, a significant improvement in treatment outcomes for this set of patients has not yet materialized. With anticipation, we await the comprehensive results from the interim evaluation of FIBROSARC, and we have high hopes for what the ultimate data will reveal."

👇Explore the most recent advancements in drug research, indications, organizations, clinical trials, results, and patents related to this target by clicking the image link below. Dive in to gain deeper insights!

According to the data provided by the Synapse Database, As of February 23, 2024, there are 1 investigational drugs for the EDB-FN and TNF-α target, including 14 indications, 1 R&D institutions involved, with related clinical trials reaching 9, and as many as 157 patents.

L19TNF is a fusion protein drug being developed for the treatment of neoplasms and nervous system diseases. Fibromun targets EDB-FN and TNF-α. EDB-FN is a protein that is overexpressed in tumor blood vessels, making it a potential target for anti-cancer therapies. With its current status in Phase 2 of development and orphan drug designation, Fibromun shows potential as a targeted therapy for specific indications such as metastatic soft tissue sarcoma and certain types of brain tumors.

图形用户界面, 文本, 网站

描述已自动生成

Unlock the Power of Synapse: A Guide to Searching Doxycycline hyclate
Drug Insights
2 min read
Unlock the Power of Synapse: A Guide to Searching Doxycycline hyclate
23 February 2024
Doxycycline hyclate, marketed under the brand name Vibramycin, is a type of antibiotic drug belonging to the tetracycline class.
Read →
Innovent's Phase 3 RESTORE-1 Study of IBI311 for Thyroid Eye Disease Hits Key Goal, Eyes NMPA Filing
Latest Hotspot
3 min read
Innovent's Phase 3 RESTORE-1 Study of IBI311 for Thyroid Eye Disease Hits Key Goal, Eyes NMPA Filing
23 February 2024
Innovent Reveals Key Goal Achieved in Phase 3 Study (RESTORE-1) of IBI311 (IGF-1R-Targeting Agent) for Thyroid Eye Condition, Intends to File for Approval with NMPA.
Read →
Decoding Infigratinib: a comprehensive study of its R&D trends and its clinical results in 2024 ASCO_GU
Decoding Infigratinib: a comprehensive study of its R&D trends and its clinical results in 2024 ASCO_GU
23 February 2024
2024 ASCO_GU presented new trial data on infigratinib, an FGFR3 inhibitor, showing promise in clinical use.
Read →
Bayer Initiates Phase II Trial of New Anti-alpha2 Antiplasmin Drug for Deep Vein Thrombosis
Latest Hotspot
3 min read
Bayer Initiates Phase II Trial of New Anti-alpha2 Antiplasmin Drug for Deep Vein Thrombosis
23 February 2024
Bayer commences a second-stage trial using a novel anti-alpha2 antiplasmin agent in individuals affected by deep venous clots.
Read →
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.